These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35963006)

  • 21. LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
    Freiberg FJ; Brynskov T; Munk MR; Sørensen TL; Wolf S; Wirth MA; Becker M; Michels S
    Retina; 2017 Dec; 37(12):2341-2346. PubMed ID: 28099318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia.
    Inman ZD; Anderson NG
    Retina; 2011 Apr; 31(4):669-72. PubMed ID: 21178659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
    Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
    Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
    Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in Kuwait.
    Wani VB; Al-Kandari J; Sabti K; Aljassar F; Qali H; Kumar N; Uboweja A; Al-Sabah K; Diab FA; Al-Rashidi S
    Middle East Afr J Ophthalmol; 2016; 23(1):64-70. PubMed ID: 26957841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lid splinting eyelid retraction technique: a minimised sterile approach for intravitreal injections.
    Munro M; Williams GR; Ells A; Fielden M; Kherani A; Mitchell P; Ruzicki J; Adatia FA
    Br J Ophthalmol; 2018 Sep; 102(9):1254-1258. PubMed ID: 29246893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aqueous Chlorhexidine for Intravitreal Injection Antisepsis: A Case Series and Review of the Literature.
    Merani R; McPherson ZE; Luckie AP; Gilhotra JS; Runciman J; Durkin S; Muecke J; Donaldson M; Aralar A; Rao A; Davies PE
    Ophthalmology; 2016 Dec; 123(12):2588-2594. PubMed ID: 27720552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection.
    Storey P; Dollin M; Pitcher J; Reddy S; Vojtko J; Vander J; Hsu J; Garg SJ;
    Ophthalmology; 2014 Jan; 121(1):283-289. PubMed ID: 24144453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
    Bavinger JC; Yu Y; VanderBeek BL
    Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
    Xu K; Chin EK; Bennett SR; Williams DF; Ryan EH; Dev S; Mittra RA; Quiram PA; Davies JB; Parke DW; Johnson JB; Cantrill HL; Almeida DRP
    Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in Endophthalmitis Associated With Intravitreal Injection of Anti-VEGF Agentsat a Tertiary Referral Center.
    Reyes-Capo DP; Yannuzzi NA; Smiddy WE; Flynn HW;
    Ophthalmic Surg Lasers Imaging Retina; 2021 Jun; 52(6):319-326. PubMed ID: 34185586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic Immunosuppression and Risk of Endophthalmitis After Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Patel SN; Storey PP; Kim JS; Obeid A; Pancholy M; Hsu J; Garg SJ
    Ophthalmic Surg Lasers Imaging Retina; 2021 Jul; 52(S1):S17-S22. PubMed ID: 34310237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seasonal and Environmental Variations in Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor Injection: A Six-year Review.
    Patel SN; Mokhashi N; Peck TJ; Cai LZ; Salabati M; Soares RR; Hinkle J; Chaudhary V; Kuriyan AE; Cohen MN; Hsu J; Garg SJ
    Curr Eye Res; 2022 Sep; 47(9):1288-1293. PubMed ID: 35759609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy.
    Lima LH; Zweifel SA; Engelbert M; Sorenson JA; Slakter JS; Cooney MJ; Klancnik JM; Yannuzzi LA; Freund KB
    Retina; 2009 Oct; 29(9):1213-7. PubMed ID: 19934815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
    Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
    Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endophthalmitis after resident-performed intravitreal bevacizumab injection.
    Falavarjani KG; Aghamirsalim M; Modarres M; Hadavandkhani A; Hashemi M; Parvaresh MM; Naseripour M; Samiy N
    Can J Ophthalmol; 2015 Feb; 50(1):33-6. PubMed ID: 25677280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a Strict 'No-Talking' Policy During Intravitreal Injection on Post-Injection Endophthalmitis.
    Garg SJ; Dollin M; Hsu J; Storey P; Vander JF
    Ophthalmic Surg Lasers Imaging Retina; 2015; 46(10):1028-34. PubMed ID: 26599245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LONG-TERM VISUAL OUTCOMES AND CLINICAL FEATURES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION-RELATED ENDOPHTHALMITIS.
    Rayess N; Obeid A; Storey PP; Juliano J; Rahimy E; Moshfeghi AA; Garg S; Hsu J
    Retina; 2019 Nov; 39(11):2070-2076. PubMed ID: 30157114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RELATIVE QUIESCENCE OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION AFTER RESOLUTION OF POSTINJECTION ENDOPHTHALMITIS.
    Arnett JJ; Brodowska K; Gallagher DS; Eller AW; Friberg TR; Anetakis AJ; Martel JN
    Retina; 2020 Sep; 40(9):1719-1723. PubMed ID: 31800459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
    Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.